EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Comparative 28-day Outcomes of Pulse-Dose Methylprednisolone versus Prolonged Low-Dose Dexamethasone in Hospitalized COVID-19 Pneumonia: A Cohort Study

Pitsucha Sanguanwit, Poonyanutch Rinprasertmeechai, Sittichok Leela-Amornsin

Archives of Academic Emergency Medicine · 01.09.2026

DOI: 10.22037/aaem.v14i1.3063 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Archives of Academic Emergency Medicine, erschienen am 01.09.2026. Verfasst von Pitsucha Sanguanwit und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Corticosteroids are widely used in COVID-19 pneumonia; however, the optimal regimen remains uncertain. We compared clinical outcomes between pulse-dose methylprednisolone and prolonged low-dose dexamethasone in hospitalized patients with COVID-19 pneumonia.

Methods

In this retrospective cohort study, adult patients hospitalized with COVID-19 pneumonia (18 April–30 August 2021), who received either pulse-dose methylprednisolone or prolonged low-dose dexamethasone, were compared regarding 28-day mortality, in-hospital mortality, and treatment-free days. Multivariable Cox regression and propensity score matching (PSM) were used to adjust for confounding.

Results

Among 460 patients (269 pulse-dose methylprednisolone, 191 prolonged low-dose dexamethasone), no significant difference in 28-day mortality was observed in multivariable analysis (aHR: 1.51; 95% CI: 0.74–3.09, p = 0.26). After PSM, 28-day mortality remained similar (HR: 1.40; 95% CI: 0.64–3.06; p = 0.38), although a trend toward higher in-hospital mortality was noted with pulse-dose methylprednisolone (HR: 2.07; 95% CI: 0.96–4.42; p = 0.06).

Conclusion

Pulse-dose methylprednisolone was not associated with a significant difference in 28-day mortality compared with prolonged low-dose dexamethasone. A trend toward higher in-hospital mortality was observed with pulse-dose methylprednisolone, warranting cautious interpretation due to potential residual confounding.

Schlagwörter

Stichwörter der Autor:innen

COVID-19DexamethasoneMethylprednisolonePneumonia, ViralSARS-Cov-2

Autor:innen und Institutionen

  • Department of Emergency Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.
  • Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, 10540, Thailand.

Zitieren

APA

Sanguanwit, P., Rinprasertmeechai, P., & Leela-Amornsin, S. (2026). Comparative 28-day Outcomes of Pulse-Dose Methylprednisolone versus Prolonged Low-Dose Dexamethasone in Hospitalized COVID-19 Pneumonia: A Cohort Study. Archives of Academic Emergency Medicine. https://doi.org/10.22037/aaem.v14i1.3063

Vancouver

Sanguanwit P, Rinprasertmeechai P, Leela-Amornsin S. Comparative 28-day Outcomes of Pulse-Dose Methylprednisolone versus Prolonged Low-Dose Dexamethasone in Hospitalized COVID-19 Pneumonia: A Cohort Study. Archives of Academic Emergency Medicine. 2026. doi:10.22037/aaem.v14i1.3063

BibTeX
@article{Sanguanwit2026,
  author = {Sanguanwit, Pitsucha and Rinprasertmeechai, Poonyanutch and Leela-Amornsin, Sittichok},
  title = {Comparative 28-day Outcomes of Pulse-Dose Methylprednisolone versus Prolonged Low-Dose Dexamethasone in Hospitalized COVID-19 Pneumonia: A Cohort Study},
  journal = {Archives of Academic Emergency Medicine},
  year = {2026},
  doi = {10.22037/aaem.v14i1.3063}
}
Kostenlos starten →